{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:19:08Z","timestamp":1790705948873,"version":"4.1.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Postthrombotic syndrome (PTS) is a frequent complication of venous thromboembolism (VTE). Using MarketScan claims data from January 2012 to June 2015, we identified adults with a primary diagnosis code for VTE during a hospitalization\/emergency department visit, \u22656 months of insurance coverage prior to the index event and newly started on rivaroxaban or warfarin within 30 days of the index VTE. Patients with &lt;4-month follow-up postindex event or a claim for any anticoagulant during 6-month baseline period were excluded. Differences in baseline characteristics between rivaroxaban and warfarin users were adjusted for using inverse probability of treatment weights based on propensity scores. Patients were followed for the development of PTS starting 3 months after the index VTE. Cox regression was performed and reported as hazard ratios with 95% confidence intervals (CIs). In total, 10 463 rivaroxaban and 26 494 warfarin users were followed for a mean of 16 \u00b1 9 (range, 4-39) months. Duration of anticoagulation was similar between cohorts (median = 6 months). Rivaroxaban was associated with a 23% (95% CI: 16-30) reduced hazard of PTS versus warfarin. Rivaroxaban was associated with a significant risk reduction in symptoms of PTS compared to warfarin in patients with VTE treated in routine practice.<\/jats:p>","DOI":"10.1177\/1076029618758955","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T03:25:52Z","timestamp":1520479552000},"page":"575-582","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":24,"title":["Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-7158","authenticated-orcid":false,"given":"Craig I.","family":"Coleman","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[{"name":"Division Hematology, Department of Medicine I, Thrombosis Research Unit, University Hospital \u201cCarl Gustav Carus\u201d Dresden, Dresden, Germany"},{"name":"Department of Hematology, Kings Thrombosis Service, Kings College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Bunz","sequence":"additional","affiliation":[{"name":"New England Health Analytics, LLC, Granby, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Mahan","sequence":"additional","affiliation":[{"name":"Presbyterian Healthcare Services, University of New Mexico, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C.","family":"Spyropoulos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health System, Hofstra Northwell School of Medicine, Manhasset, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"key":"bibr1-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000130"},{"key":"bibr2-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2000.06419.x"},{"key":"bibr3-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04516.x"},{"key":"bibr4-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.05.035"},{"key":"bibr5-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042269"},{"key":"bibr6-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01333.x"},{"key":"bibr7-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04872.x"},{"key":"bibr8-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"bibr9-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"bibr10-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-11-21"},{"key":"bibr11-1076029618758955","unstructured":"Xarelto (rivaroxaban) prescribing information [revised 08\/2016]. https:\/\/www.xareltohcp.com\/shared\/product\/xarelto\/prescribing-information.pdf (Last accessed on January 9, 2017)."},{"key":"bibr12-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-01-0041"},{"key":"bibr13-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"bibr14-1076029618758955","unstructured":"Hansen L. The Truven Health MarketScan Databases for life sciences researchers. 2017; https:\/\/truvenhealth.com\/Portals\/0\/Assets\/2017-MarketScan-Databases-Life-Sciences-Researchers-WP.pdf [Accessed October 8, 2017]."},{"key":"bibr15-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000524"},{"key":"bibr16-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2301"},{"key":"bibr17-1076029618758955","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-98-6-891"},{"key":"bibr18-1076029618758955","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060388"},{"key":"bibr19-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-05-0425"},{"issue":"5","key":"bibr20-1076029618758955","first-page":"363","volume":"18","author":"Lefebvre P","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"bibr21-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03294.x"},{"key":"bibr22-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"issue":"1","key":"bibr23-1076029618758955","first-page":"158a","volume":"24","author":"Villalta S","year":"1994","journal-title":"Haemostasis"},{"key":"bibr24-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-015-1310-7"},{"key":"bibr25-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.668020"},{"key":"bibr26-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-02-0152"},{"key":"bibr27-1076029618758955","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00957.x"},{"key":"bibr28-1076029618758955","first-page":"215","volume":"5","author":"Gandhi SK","year":"1999","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr29-1076029618758955","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080507"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029618758955","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1076029618758955","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029618758955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:07:14Z","timestamp":1777385234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1076029618758955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1177\/1076029618758955"],"URL":"https:\/\/doi.org\/10.1177\/1076029618758955","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,8]]}}}